COMPOSITIONS AND METHODS RELATED TO RAD51 INACTIVATION IN THE TREATMENT OF NEOPLASTIC DISEASES, AND ESPECIALLY CML

摘要

Chronic myelogenous leukemia (CML), and in particular imatinib resistant CML is treated using compositions and methods in which a Rad51-inhibitor and a kinase inhibitor are administered. Most preferably, the Rad51 inhibitor comprises an indolyl isoquinoline structure and the kinase inhibitor is a BCR-ABL inhibitor.